<DOC>
	<DOCNO>NCT00359567</DOCNO>
	<brief_summary>To compare palonosetron granisetron hydrochloride control efficacy intravenous single dose prevent acute delay gastro-intestinal disorder , nausea vomit induce highly emetogenic chemotherapy .</brief_summary>
	<brief_title>Comparative Study Palonosetron With Granisetron Control Patients Receiving Highly Emetogenic Chemotherapy</brief_title>
	<detailed_description>This study involve prophylactic single dose granisetron hydrochloride control treatment chemotherapy induce nausea vomiting ( CINV ) . The primary objective study verify 0.75 mg palonosetron , concomitantly administer corticosteroid , inferior superior granisetron hydrochloride acute stag 0 - 24 hour delay stage 24 - 120 hour administration highly emetogenic chemotherapy , respectively . Corticosteroids commonly employ current medical treatment 5-HT3 receptor antagonist . This multicenter , parallel , group comparative study subject assign treatment group accordance central registration system . After obtain write informed consent , patient satisfy inclusion criterion without meet exclusion criterion assign use minimize procedure either single-dose 0.75 mg palonosetron group single-dose 40 μg/kg granisetron hydrochloride covariates chemotherapy regimen , gender age . A palonosetron group receive intravenous injection 0.75 mg palonosetron ( 5 mL ) granisetron placebo administration highly emetogenic chemotherapy . A granisetron hydrochloride group treat palonosetron placebo intravenous 40μg/kg granisetron hydrochloride administration highly emetogenic chemotherapy . The onset nausea emetic episode time antiemetic procedure observe 120 hour start highly emetogenic chemotherapy . The objective find patient ' global satisfaction antiemetic therapy . Adverse event also observe seven day administration drug .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Patients age 20 time give consent . Diagnosed malignant disease . Be naive chemotherapy treat single administration antitumor drug classify low emetogenicity first edition 2006 NCCN Clinical Practice Guidelines . Cisplatin ≥50 mg/m2 Doxorubicin + cyclophosphamide : AC Epirubicin + cyclophosphamide : EC WBC ≥ 3000 /mm3 AST &lt; 100 IU/L ALT &lt; 100 IU/L Creatinine clearance ≥ 60 mL/min Performance Status : 0 2 Severe ( require hospitalization ) uncontrollable complication . Metastases brain symptomatic . Seizure disorder require anticonvulsant medication unless clinically stable free seizure activity . Symptomatic invasive procedure indicate ascites pleural effusion . Have either gastric outlet stenosis intestinal obstruction . Have ongoing emesis CTCAE grade 2 great nausea . QTc &gt; 470 msec 12lead ECG within eight day registration . Known anaphylactic ingredient study drug , namely palonosetron granisetron hydrochloride injection , 5HT3 receptor antagonist . Known anaphylactic ingredient dexamethasone . Pregnant woman , breastfeed woman , male female willing practice adequate contraception study period .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>nausea vomit</keyword>
</DOC>